Polylactic acid
Based on 1 Customer Validation
Polylactic acid (PLA) is a biodegradable and biocompatible polymer widely used as a carrier for drug delivery systems and a structural material for tissue engineering and medical implants. Polylactic acid acts as a controlled release matrix through the hydrolysis mechanism of ester bonds, gradually releasing the encapsulated drug and metabolizing to non-toxic lactic acid. Polylactic acid has adjustable degradation rate, mechanical properties and the ability to composite with other polymers, and can be used in local or systemic drug delivery, orthopedic fixation devices and 3D printed bone regeneration scaffolds.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 26100-51-6
- 分子式: (C3H6O3)x
- 分子量:60000(Average)
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
26.61 mM
Compound: Lactic acid
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25299679] |
| MRC5 | IC50 |
23.93 mM
Compound: Lactic acid
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25299679] |
Polylactic acid (PLA) showed more efficient release of 5-Fluorouracil (HY-90006) than pure polymer in electrospun hybrid nanofibers of 80:20 PLA/PCL ratio (20 g/L glucose). PLA microspheres (10 mg/mL; 35 days) achieved sustained release of Naltrexone (HY-76711) with a cumulative release rate of 67%. 3D-printed PLA/hydroxyapatite scaffolds (2 weeks in vivo) promoted osteoblast proliferation and bone formation in rabbit calvarial defects. PLA-based drug-eluting scaffolds (10 μg /cm2; 30 days) achieved controlled release of paclitaxel and reduced restenosis rate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 26100-51-6
-
性状 Solid
-
分子量 60000(Average)
-
分子式 (C3H6O3)x
-
Color White to off-white
-
SMILES
O=C(C(C)O)O.[x]
-
別名
PLA
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
DMSO : 200 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
純度とドキュメンテーション
-
データシート (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Polylactic acid 関連分類
HY-W250313 関連分類
Powered by Bioz